Exact Sciences Corp EXAS
We take great care to ensure that the data presented and summarized in this overview for EXACT SCIENCES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EXAS
View all-
Vanguard Group Inc Valley Forge, PA17.8MShares$1.1 Billion0.02% of portfolio
-
Capital World Investors Los Angeles, CA15.8MShares$977 Million0.17% of portfolio
-
Wellington Management Group LLP Boston, MA14.3MShares$884 Million0.18% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$744 Million0.01% of portfolio
-
State Street Corp Boston, MA6.68MShares$412 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY5.26MShares$324 Million0.03% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN4.53MShares$279 Million0.08% of portfolio
-
William Blair Investment Management, LLC Chicago, IL4.28MShares$264 Million0.75% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.81MShares$235 Million0.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.39MShares$209 Million0.14% of portfolio
Latest Institutional Activity in EXAS
Top Purchases
Top Sells
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Insider Transactions at EXAS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 13
2024
|
Kevin T Conroy President and CEO |
BUY
Open market or private purchase
|
Direct |
19,500
+1.78%
|
$994,500
$51.35 P/Share
|
|
Oct 08
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
929
-6.79%
|
$65,030
$70.0 P/Share
|
|
Sep 18
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
929
-6.36%
|
$65,030
$70.0 P/Share
|
|
Aug 05
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-8.6%
|
$75,625
$55.77 P/Share
|
|
Aug 05
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
2,712
+14.5%
|
-
|
|
Jun 13
2024
|
Michael J Barber |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+50.0%
|
-
|
|
Jun 13
2024
|
Shacey Petrovic |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+25.49%
|
-
|
|
Jun 13
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+9.8%
|
-
|
|
Jun 13
2024
|
Daniel J Levangie |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+16.08%
|
-
|
|
Jun 13
2024
|
Katherine S Zanotti |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+7.21%
|
-
|
|
Jun 13
2024
|
Paul J Clancy |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+21.27%
|
-
|
|
Jun 13
2024
|
Kathleen Sebelius |
BUY
Grant, award, or other acquisition
|
Direct |
6,889
+17.77%
|
-
|
|
Jun 13
2024
|
James Edward Doyle |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+8.92%
|
-
|
|
May 01
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
1,155
-0.1%
|
$69,300
$60.15 P/Share
|
|
May 01
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
102
-0.7%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
102
-0.14%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
110
-0.82%
|
$6,600
$60.15 P/Share
|
|
May 01
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
136
-1.14%
|
$8,160
$60.15 P/Share
|
|
May 01
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
30
-0.3%
|
$1,800
$60.15 P/Share
|
|
May 01
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
136
-0.29%
|
$8,160
$60.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 89.9K shares |
|---|---|
| Exercise of conversion of derivative security | 256K shares |
| Open market or private purchase | 19.5K shares |
| Payment of exercise price or tax liability | 62.9K shares |
|---|---|
| Open market or private sale | 110K shares |